CNSP CNS Pharmaceuticals
- 0.1996
- -0.0081-3.90%
- 0.2070
- +0.0074+3.71%
CNS Pharmaceuticals News
Express News | CNS Pharmaceuticals Q1 EPS $(0.41) Up From $(2.59) YoY
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing the most aggressive type of brain cancer with an average survival of
CNS Pharmaceuticals | 10-Q: Quarterly report
Express News | CNS Pharmaceuticals Inc Files for Mixed Shelf of up to $75 Mln - SEC Filing
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
CNS Pharmaceuticals Enacts Key Corporate Governance Changes
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersAdial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwa
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity Download as PDF April 22, 2024 12:00am EDT Live video webcast with Chief Executive Officer, John Climaco,
CNS Pharmaceuticals Conducts Informational Investor Meetings
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR
Express News | CNS Pharmaceuticals Q4 EPS $(0.95) Up From $(3.82) YoY
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
ead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM study.
CNS Pharmaceuticals to Present at Two Investor Conferences in April
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April.
CNS Pharmaceuticals Strives to Regain Nasdaq Compliance
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersNanoString Technologies (NASDAQ:NSTG) shares moved upwards by 16.5% to $0.06 during Wednesday's after-market session. The market value of their outstanding shares is at $2.9 million. Tenax Ther
Express News | CNS Pharmaceuticals Shares Are Trading Lower After the Company Announced Pricing of a $4 Million Public Offering
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was also 0.1% lower in Tuesday's premarket activity as traders cautious
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAgape ATP (NASDAQ:ATPC) shares rose 92.1% to $0.98 during Tuesday's pre-market session. The company's market cap stands at $75.5 million. Jin Medical International (NASDAQ:ZJYL) stock moved upw
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell
CNS Pharmaceuticals (CNSP) said Monday it priced a public offering of about 13.3 million common shares at $0.30 per share. The company also agreed to issue to investors series A warrants to purchase u
Analysis
Price Target
No Data
